These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26233533)

  • 21. Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Thysell E; Ylitalo EB; Jernberg E; Bergh A; Wikström P
    Eur Urol; 2017 Oct; 72(4):e104-e105. PubMed ID: 28642023
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Axel Heidenreich, David Pfister. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care. Eur Urol 2012;62:1201-4.
    Brookman-May S; Tombal B; Joniau S
    Eur Urol; 2013 Sep; 64(3):e62-4. PubMed ID: 23582882
    [No Abstract]   [Full Text] [Related]  

  • 23. Simultaneous targeting of the Akt and androgen receptor pathways.
    Wirth MP; Froehner M
    Eur Urol; 2015 Jun; 67(6):991-992. PubMed ID: 25199717
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2018 Jan; 73(1):e11-e12. PubMed ID: 28801127
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
    Mehra N; Dolling D; de Bono J
    Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 May; 195(5):1472-1473. PubMed ID: 27186729
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer: Fitting to overcome enzalutamide resistance.
    Thoma C
    Nat Rev Urol; 2016 Oct; 13(10):564-5. PubMed ID: 27549359
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate cancer: Enzalutamide-cabazitaxel interactions.
    Kelsey R
    Nat Rev Urol; 2018 Feb; 15(2):69. PubMed ID: 29231199
    [No Abstract]   [Full Text] [Related]  

  • 30. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
    Francini E; Roviello G
    Tumour Biol; 2014 Aug; 35(8):7391-2. PubMed ID: 24874054
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Azad AA; Chi KN
    Eur Urol; 2015 Sep; 68(3):e57-8. PubMed ID: 25864159
    [No Abstract]   [Full Text] [Related]  

  • 32. Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Culig Z
    Eur Urol; 2018 Jan; 73(1):9-10. PubMed ID: 28890248
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer.
    Li H; Zhang Y; Xu H
    Eur Urol; 2022 Nov; 82(5):e137-e138. PubMed ID: 36088181
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Heidegger I; Pichler R; Pircher A
    Eur Urol; 2017 Oct; 72(4):e102-e103. PubMed ID: 28602201
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate Cancer: Box clever--YB-1 has a role in CRPC.
    Stone L
    Nat Rev Urol; 2016 Apr; 13(4):183. PubMed ID: 26902340
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Cronauer MV; Merseburger AS; Hoda MR
    Eur Urol; 2017 Apr; 71(4):e105-e106. PubMed ID: 27663049
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209520
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer: understanding why.
    McCarthy N
    Nat Rev Cancer; 2013 Nov; 13(11):754. PubMed ID: 24108098
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.
    Li X; Xu Z; Qi F
    Eur Urol; 2024 Jan; 85(1):e14. PubMed ID: 37596190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.